Financiere des Professionnels Fonds d investissement inc. Takes $230,000 Position in Medpace Holdings, Inc. $MEDP

Key Points

• Financiere des Professionnels Fonds d'investissement inc. has invested $230,000 in Medpace Holdings by acquiring 732 shares in the second quarter.
• Several large investors have increased their stakes in Medpace, with Northern Trust Corp. raising their investment by 36% during the first quarter.
• Analysts have mixed views on Medpace's stock, with Barclays raising the target price to $450 while other firms have downgraded their ratings.

Financiere des Professionnels Fonds d investissement inc. acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 732 shares of the company's stock, valued at approximately $230,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in MEDP. Geneos Wealth Management Inc. lifted its holdings in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. Brooklyn Investment Group lifted its holdings in shares of Medpace by 244.8% during the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after purchasing an additional 71 shares during the last quarter. Whittier Trust Co. lifted its holdings in shares of Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after purchasing an additional 35 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Medpace during the 1st quarter valued at $60,000. Finally, Assetmark Inc. lifted its holdings in shares of Medpace by 24.9% during the 1st quarter. Assetmark Inc. now owns 216 shares of the company's stock valued at $66,000 after purchasing an additional 43 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Barclays upped their target price on Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 23rd. Cowen cut Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. Rothschild & Co Redburn lowered shares of Medpace from a "buy" rating to a "neutral" rating and raised their target price for the stock from $342.00 to $474.00 in a research note on Wednesday, September 3rd. Rothschild Redb lowered shares of Medpace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, September 3rd. Finally, TD Cowen reiterated a "sell" rating and issued a $366.00 target price (up previously from $283.00) on shares of Medpace in a report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, Medpace has a consensus rating of "Reduce" and an average price target of $422.27.

Medpace Stock Performance

MEDP traded down $3.34 on Friday, hitting $498.60. 744,026 shares of the company were exchanged, compared to its average volume of 295,741. The business's fifty day moving average is $446.89 and its 200 day moving average is $355.24. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $506.55. The firm has a market capitalization of $14.01 billion, a P/E ratio of 37.07, a price-to-earnings-growth ratio of 3.14 and a beta of 1.44.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating the consensus estimate of $3.00 by $0.10. The business had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The company's quarterly revenue was up 14.2% on a year-over-year basis. During the same period in the prior year, the business earned $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Activity at Medpace

In other news, President Jesse J. Geiger sold 41,801 shares of the firm's stock in a transaction on Thursday, July 24th. The shares were sold at an average price of $453.11, for a total value of $18,940,451.11. Following the transaction, the president owned 36,503 shares of the company's stock, valued at approximately $16,539,874.33. This trade represents a 53.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the firm's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the sale, the general counsel directly owned 10,343 shares of the company's stock, valued at approximately $4,654,350. The trade was a 22.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 161,266 shares of company stock valued at $74,111,427 over the last 90 days. 20.30% of the stock is currently owned by insiders.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.